1252 studies found for:    "Macular Degeneration"
Show Display Options
Rank Status Study
21 Recruiting Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration
Condition: Age-related Macular Degeneration
Intervention: Drug: Ranibizumab 0.5mg
22 Completed
Has Results
Pilot Study of Lucentis Combined With Proton Beam Irradiation in Treating Wet Age-related Macular Degeneration
Condition: Age-related Macular Degeneration
Intervention: Drug: Proton beam irradiation and ranibizumab
23 Recruiting A Pharmacokinetic Study of Intravitreal Aflibercept Injection in Vitrectomized and Non-vitrectomized Eyes With Wet Age-related Macular Degeneration (DRAW).
Condition: Neovascular Macular Degeneration
Intervention: Drug: Aflibercept
24 Completed
Has Results
A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR)
Condition: Age-related Macular Degeneration
Intervention: Drug: Ranibizumab
25 Unknown  Safety Study for Treatment of Wet Macular Degeneration Using the TheraSight(TM) Ocular Brachytherapy System
Conditions: Macular Degeneration;   Choroidal Neovascularization
Intervention: Device: Ocular Brachytherapy
26 Completed Palomid 529 in Patients With Neovascular Age-Related Macular Degeneration
Condition: Age-Related Macular Degeneration
Intervention: Drug: Palomid 529
27 Completed
Has Results
Ocular Safety Of Patients Receiving Macugen For Neovascular Age Related Macular Degeneration
Condition: Macular Degeneration
Intervention: Drug: Macugen
28 Terminated 12 Week Patient Study in Neovascular Age-related Macular Degeneration (AMD)
Condition: Macular Degeneration
Intervention: Drug: pazopanib eye drops
29 Completed Study of AdGVPEDF.11D in Neovascular Age-related Macular Degeneration (AMD)
Condition: Macular Degeneration
Intervention: Drug: AdGVPEDF.11D
30 Recruiting Treatment of Age-related Macular Degeneration by Fetal Retinal Pigment Epithelial Cells Transplantation
Conditions: Age Related Macular Degeneration;   Macular Degeneration;   AMD
Intervention: Drug: fRPE cells
31 Completed Anecortave Acetate in Patients With Exudative Age-related Macular Degeneration (AMD)
Condition: Macular Degeneration
Interventions: Drug: Anecortave Acetate Sterile Suspension, 30 mg/mL;   Drug: Anecortave Acetate Sterile Suspension, 60 mg/mL;   Other: Anecortave Acetate Vehicle
32 Active, not recruiting Safety and Tolerability Study of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration (AMD)
Conditions: Macular Degeneration;   Age-Related Maculopathies;   Age-Related Maculopathy;   Maculopathies, Age-Related;   Maculopathy, Age-Related;   Retinal Degeneration;   Retinal Neovascularization;   Gene Therapy;   Therapy, Gene;   Eye Diseases
Intervention: Biological: AAV2-sFLT01
33 Completed A Study to Evaluate Pazopanib Tablets in Patients Who Have Neovascular Age-related Macular Degeneration
Condition: Macular Degeneration
Intervention: Drug: Pazopanib
34 Active, not recruiting Caregiver Burden of Wet Age-related Macular Degeneration (wAMD) in Japan
Condition: Wet Macular Degeneration
Intervention: Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
35 Completed Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
Condition: Macular Degeneration
Interventions: Drug: Regorafenib, ophthalmic oily suspension (BAY73-4506);   Procedure: Sham IVT;   Drug: Ranibizumab;   Drug: Placebo
36 Completed Celecoxib to Treat Macular Degeneration in Patients Receiving Photodynamic Therapy
Condition: Macular Degeneration
Intervention: Drug: Celecoxib
37 Completed Extension Study of rhuFab V2 in Subjects With Neovascular Age-Related Macular Degeneration (AMD)
Condition: Macular Degeneration
Intervention: Drug: rhuFab V2 (ranibizumab)
38 Completed Pilot Study of Ranibizumab With and Without Ketorolac Eyedrops for Exudative Age-related Macular Degeneration
Condition: Wet Macular Degeneration
Interventions: Drug: Ketorolac + Ranibizumab;   Drug: Ranibizumab
39 Completed A Study to Evaluate rhuFab V2 in Subjects With Minimally Classic or Occult Subfoveal Neovascular Macular Degeneration
Condition: Macular Degeneration
Intervention: Drug: rhuFab V2 (ranibizumab)
40 Recruiting Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
Condition: Macular Degeneration
Intervention: Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years